Scarica l'app Stockscreener
21.76
17.43%
3.23
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GPCR Giù?
Forum
Previsione
Precedente Chiudi:
$18.53
Aprire:
$21.5
Volume 24 ore:
5.81M
Relative Volume:
6.49
Capitalizzazione di mercato:
$1.09B
Reddito:
-
Utile/perdita netta:
$-100.44M
Rapporto P/E:
-9.8018
EPS:
-2.22
Flusso di cassa netto:
$-105.32M
1 W Prestazione:
+44.58%
1M Prestazione:
-0.14%
6M Prestazione:
-45.08%
1 anno Prestazione:
-41.30%
Intervallo 1D:
$19.74
$24.17
Intervallo di 1 settimana:
$15.00
$24.17
Portata 52W:
$13.22
$62.74
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Nome
Structure Therapeutics Inc Adr
Settore
Industria
Telefono
(628) 229-9277
Indirizzo
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
Confronta GPCR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
21.76 | 1.09B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-28 | Iniziato | William Blair | Outperform |
| 2025-01-08 | Iniziato | Stifel | Buy |
| 2024-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-05-21 | Iniziato | JP Morgan | Overweight |
| 2024-04-09 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-07-27 | Iniziato | Piper Sandler | Overweight |
| 2023-05-25 | Ripresa | Jefferies | Buy |
| 2023-02-28 | Iniziato | BMO Capital Markets | Outperform |
| 2023-02-28 | Iniziato | Guggenheim | Buy |
| 2023-02-28 | Iniziato | Jefferies | Buy |
| 2023-02-28 | Iniziato | SVB Securities | Outperform |
Mostra tutto
Structure Therapeutics Inc Adr Borsa (GPCR) Ultime notizie
Structure Therapeutics Inc ADR (NASDAQ: GPCR) Stock: A Value Hunter’s Investment? - stocksregister.com
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback - Yahoo Finance
Structure Therapeutics shares rise on Pfizer’s obesity drug exit By Investing.com - Investing.com Canada
Structure Therapeutics shares rise on Pfizer’s obesity drug exit - Investing.com
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today - The Motley Fool
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
What is Iterum Therapeutics Plc (ITRM) Stock Return on Shareholders’ Capital? - Sete News
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Apellis Pharmaceuticals (APLS) - The Globe and Mail
Cognito Therapeutics Announces Spectris™ Data Demonstrating Brain Structural Maintenance and Mechanism of Action in Alzheimer’s Disease at AD/PD™ 2025 - Business Wire
Predicting Upstart Holdings Inc’s (UPST) earnings for the current quarter - uspostnews.com
GPCR stock touches 52-week low at $19.29 amid market challenges - Investing.com Canada
Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) PT at $81.29 - Defense World
Cognito Therapeutics to Present New Data on Spectris’™ Impact on Brain Structure in Alzheimer’s Disease at AD/PD 2025 - Business Wire
Structure Therapeutics CEO on latest GLP-1 developments - CNBC
Oral Proteins and Peptides Market Know the Scope and Trends As Revealed In New Report - WhaTech
Analysts Are Bullish on Top Healthcare Stocks: Quanterix (QTRX), Xoma (XOMA) - The Globe and Mail
Acute Bacterial Skin and Skin-Structure Infection Market - openPR
Jones Financial Companies Lllp Raises Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Bought by Assetmark Inc. - Defense World
Analysts Update Their Estimates For Structure Therapeutics Inc ADR - Stocks Register
GPCR Stock Hits 52-Week Low at $19.61 Amid Market Challenges - Investing.com Canada
Berberine-inspired ionizable lipid for self-structure stabilization and brain targeting delivery of nucleic acid therapeutics - Nature.com
Archer Aviation Stock Climbs as Midnight eVTOL Nears Reality - The Globe and Mail
Structure Therapeutics (GPCR) Projected to Post Quarterly Earnings on Friday - Defense World
Research Analysts Issue Forecasts for GPCR Q4 Earnings - Defense World
Q1 Earnings Estimate for GPCR Issued By Leerink Partnrs - Defense World
Structure Therapeutics, Inc.: Strong Pipeline and Financial Stability Underpin Buy Rating Despite Price Target Reduction - TipRanks
Structure Therapeutics Inc ADR’s (NASDAQ: GPCR) Stock Price Continues To Fall - Stocks Register
Leerink cuts Structure Therapeutics target to $60, keeps outperform - Investing.com India
Structure Therapeutics (NASDAQ:GPCR) Research Coverage Started at William Blair - Defense World
Heron Therapeutics’ (HRTX) Buy Rating Reiterated at Needham & Company LLC - Defense World
Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $81.29 - Defense World
Structure Therapeutics (NASDAQ:GPCR) Coverage Initiated by Analysts at William Blair - MarketBeat
Structure Therapeutics Advances in Obesity Treatment Pipeline - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Up 8% on Earnings Beat - MarketBeat
Structure Therapeutics, Inc.: Promising Outlook with Aleniglipron in Obesity Treatment and Strategic Advancements Justify Buy Rating - TipRanks
Promising Potential of Structure Therapeutics’ Aleniglipron: A Compelling Buy Recommendation - TipRanks
JMP cuts Structure Therapeutics price target to $87 - Investing.com
Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $81.29 Average Price Target from Brokerages - MarketBeat
Buy Rating for Structure Therapeutics: Promising Phase 2b Trials and Strong Financial Position - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Hits New 52-Week LowTime to Sell? - MarketBeat
Structure Therapeutics reports Q4 net loss $36.5M vs. net loss $24.5M last year - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Trading Down 6.4%Time to Sell? - MarketBeat
Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights - The Manila Times
Can Structure Therapeutics' Obesity Drug Challenge Wegovy? Trial Enrollment Complete - StockTitan
GPCR stock touches 52-week low at $20.11 amid market challenges By Investing.com - Investing.com South Africa
GPCR stock touches 52-week low at $20.11 amid market challenges - Investing.com India
Structure Therapeutics (NASDAQ:GPCR) Trading Up 6.2%Here's Why - MarketBeat
Handelsbanken Fonder AB Purchases Shares of 165,000 Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc. (NASDAQ:GPCR) Sees Large Decline in Short Interest - MarketBeat
Structure Therapeutics Inc Adr Azioni (GPCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):